iBio Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Significant Transactions (Details)

Significant Transactions (Details)						3 Months Ended			12 Months Ended
Significant Transactions (Details)	Feb. 25, 2024 USD ($)	Jan. 01, 2023	Sep. 16, 2022 USD ($) shares	Nov. 01, 2021 USD ($) $ / shares shares	Aug. 23, 2021 USD ($) shares	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)	Jun. 30, 2022 USD ($)	Sep. 16, 2022	Sep. 16, 2022 lease
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
General and administrative expenses						$ 2,801,000	$ 3,547,000
PD-1 Asset Purchase Agreement \| Otsuka Pharmaceutical \| Intellectual Property
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from sale of intellectual property	$ 1,000,000.0
Potential contingent payments related to sale of intellectual property	$ 52,500,000
The Purchase and Sale Agreement \| College Station Investors
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Purchase price for Ground Lease Property				$ 28,750,000
Proceeds from sale of building				28,000,000
Base rent expense				$ 151,450
Interest rate on lease (percentage of facility's market value)				6.50%
The Credit Agreement \| Woodforest National Bank
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Principal amount borrowed				$ 22,375,000
The Warrant \| Bryan Capital \| iBio Common Stock
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrants, shares issued \| shares				2,579
Exercise price per share of warrants \| $ / shares				$ 665
Warrants issued and exercisable \| shares				579
Value of exercisable warrants				$ 217,255
Collaboration, Option and License Agreement \| RubrYc Therapeutics
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration and license agreement, agreement term					5 years
Collaboration and license agreement, royalty payment term					10 years
Stock Purchase Agreement \| RubrYc Therapeutics \| Series A-2 Preferred Stock
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares purchased in transaction \| shares					2,864,345
Value of shares purchased in transaction					$ 7,500,000
Asset Purchase Agreement \| RubrYc Therapeutics
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Liability for contingent consideration			$ 5,000,000
Cash advances to RubrYc to support operations			484,000
Transaction costs			208,000
Impairment of investment in RubrYc									$ 1,760,000
Impairment of current prepaid expense									288,000
Impairment of noncurrent prepaid expense									$ 864,000
Number of equipment leases assumed in asset acquisition										3	3
Financing lease liabilities assumed in acquisition			$ 814,000
Asset Purchase Agreement \| RubrYc Therapeutics \| iBio Common Stock
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares issued per agreement \| shares			5,117
Fair value of shares issued in agreement			$ 1,000,000
Fair value of shares issued and subject to lockup period			$ 650,000
Separation Agreement and General Release \| Mr. Thomas F. Isett, Former Chief Executive Officer
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Period of bi-monthly installments of current base salary		24 months
Period of bi-monthly installments of target bonus		24 months
Maximum period for coverage of health insurance		18 months
COBRA subsidy period		18 months
Contingent lump-sum severance payment, expressed as a multiple of monthly COBRA subsidy		6
General and administrative expenses								$ 2,130,000
Accrued expenses						$ 300,000